EUVIMEDEUVIMED entdecken
Crossref

Mechanism of Action

R. Colin Blenis

JAMA · 26.05.2026 · 335 (20) · 1820

DOI: 10.1001/jama.2026.1799 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 26.05.2026. Verfasst von R. Colin Blenis. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitieren

Abstract (Originalsprache)

• These results characterize the potential efficacy for this investigational immunotherapy when used in combination with a drug such as rituximab that has a different MOA.7 Future studies Pfizer will further explore utomilumab in order to better understand its efficacy and safety when used as both a single agent and in combination with other anti-cancer therapies, including immunotherapies, in several types of studies:

Zitieren

APA

Blenis, R. C. (2026). Mechanism of Action. JAMA, 335(20), 1820. https://doi.org/10.1001/jama.2026.1799

Vancouver

Blenis RC. Mechanism of Action. JAMA. 2026;335(20):1820. doi:10.1001/jama.2026.1799

BibTeX
@article{Blenis2026,
  author = {Blenis, R. Colin},
  title = {Mechanism of Action},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {20},
  pages = {1820},
  doi = {10.1001/jama.2026.1799}
}
Kostenlos starten →